Foghorn Therapeutics Inc. (FHTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
FHTX currently has 58.7M outstanding shares. with limited dilution risk as only 7.86M additional shares (13.4%) are authorized for issuance. The company has diluted shareholders by 14.59% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 58.7M shares outstanding |
59M | 7.9M |
| Nov 05, 2025 |
10-Q filing | 56.6M shares outstanding |
57M | 7.9M |
| Aug 05, 2025 |
10-Q filing | 56.5M shares outstanding |
57M | 7.9M |
| May 14, 2025 |
10-Q filing | 55.7M shares outstanding |
56M | 7.9M |
| Mar 06, 2025 |
10-K filing | 54.9M shares outstanding |
55M | 7.9M |
| Jan 24, 2025 |
S-3 filing: This is an S-3 filing for a universal shelf offering of common stock, preferred stock, warrants, and units, with a total aggregate offering price of $300,000,000. |
56M | 7.9M |
| Nov 04, 2024 |
10-Q filing | 55.6M shares outstanding |
56M | 7.9M |
| Aug 08, 2024 |
10-Q filing | 51.6M shares outstanding |
52M | 7.9M |
| May 06, 2024 |
10-Q filing | 42.4M shares outstanding |
42M | 7.9M |
| Mar 07, 2024 |
10-K filing | 42.0M shares outstanding |
42M | 7.9M |
| Nov 02, 2023 |
10-Q filing | 42.0M shares outstanding |
42M | 7.9M |
| Aug 04, 2023 |
10-Q filing | 41.8M shares outstanding |
42M | 7.9M |
| May 08, 2023 |
10-Q filing | 41.8M shares outstanding |
42M | 7.9M |
| Mar 09, 2023 |
10-K filing | 41.6M shares outstanding |
42M | 7.9M |
| Nov 08, 2022 |
10-Q filing | 41.7M shares outstanding |
42M | 7.9M |
| Aug 09, 2022 |
10-Q filing | 41.5M shares outstanding |
42M | 7.9M |
| May 09, 2022 |
10-Q filing | 41.4M shares outstanding |
41M | 7.9M |
| Mar 10, 2022 |
10-K filing | 41.4M shares outstanding |
41M | 7.9M |
| Feb 14, 2022 |
S-3 filing: This is an S-3 filing for newly registered securities including common stock, preferred stock, warrants, and units with a total offering amount of $300,000,000. |
37M | 7.9M |
| Dec 13, 2021 |
8-K filing: Foghorn Therapeutics Inc. sold 4,000,000 shares of common stock to Eli Lilly and Company at $20.00 per share for an aggregate purchase price of $80,000,000 on December 10, 2021. ($80.0M proceeds) |
37M | 7.9M |
| Nov 09, 2021 |
10-Q filing | 37.0M shares outstanding |
37M | 7.9M |
| Aug 10, 2021 |
10-Q filing | 36.8M shares outstanding |
37M | 7.9M |
| May 11, 2021 |
10-Q filing | 36.8M shares outstanding |
37M | 7.9M |
| Mar 18, 2021 |
10-K filing | 3.5M shares outstanding |
3.5M | 7.9M |
| Dec 04, 2020 |
10-Q filing | 5.4M shares outstanding |
5.4M | 7.9M |
| Oct 22, 2020 |
S-1/A filing: This S-1/A filing includes information about a common stock offering with an option for underwriters to purchase additional shares. The company estimates net proceeds of approximately $107.8 million from the sale of common stock at an initial public offering price of $16.00 per share. |
36M | 7.9M |
| Oct 19, 2020 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock, with an option for underwriters to purchase additional shares. |
36M | 8.6M |
| Oct 02, 2020 |
S-1 filing: This is an S-1 filing related to an initial public offering of common stock. |
12M | 0 |